Table 2.
Lipid parameters with remogliflozin 100 or 250 mg vs. dapagliflozin 10 mg (24 week)
| At week 24 | Mean change from baseline | Between-group difference (95% CI); p value | |||
|---|---|---|---|---|---|
| Group 1 (REM 100 mg; n = 217) | Group 2 (REM 250 mg; n = 232) | Group 3 (DAP 10 mg; n = 132) | Group 1 vs. 3 (DAP 10 mg vs. REM 100 mg) | Group 2 vs. 3 (DAP 10 mg vs. REM 250 mg) | |
| Total cholesterol (mg/dL) | − 2.2 ± 2.62 | 0.3 ± 2.55 | − 7.1 ± 3.18 | 4.9 (− 2.4 to 12.3); 0.189 | 7.4 (0.1 to 14.7); 0.048 |
| LDL-C (mg/dL) | 4.8 ± 2.29 | 5.1 ± 2.22 | − 0.0 ± 2.79 | 4.8 (− 1.6 to 11.3); 0.142 | 5.1 (− 1.4 to 11.5); 0.121 |
| HDL-C (mg/dL) | 3.1 ± 0.74 | 3.9 ± 0.72 | 1.5 ± 0.92 | 1.5 (− 0.6 to 3.7); 0.163 | 2.3 (0.2 to 4.5); 0.032 |
| Triglycerides (mg/dL) | − 11.3 ± 4.93 | − 11.3 ± 4.78 | − 14.2 ± 5.99 | 2.9 (− 11.0 to 16.8); 0.681 | 2.9 (− 10.9 to 16.7); 0.679 |
| Total cholesterol/HDL-C | − 0.36 ± 0.07 | − 0.31 ± 0.07 | − 0.32 ± 0.09 | − 0.04 (− 0.24 to 0.16); 0.687 | 0.01 (− 0.18 to 0.21); 893 |
| HDL-C/LDL-C | − 0.00 ± 0.03 | 0.05 ± 0.03 | 0.00 ± 0.04 | − 0.00 (− 0.11 to 0.10); 0.925 | 0.04 (− 0.06 to 0.14); 0.393 |
Data are presented as mean ± standard deviation unless otherwise specified
CI confidence interval, DAP dapagliflozin, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, REM remogliflozin